中文名：CS-273;5-氯-N-(((5S)-2-氧代-3-(4-(3-氧代嗎啉-4-基)苯基)-1,3-惡唑啉-5-基)甲基)噻吩-2-甲酰胺;利伐沙班;5-氯-N-[[(5S)-2-氧代-3-[4-(3-氧代-4-嗎啉基)苯基]-5-惡唑基]甲基]-2-噻吩甲酰胺;利伐沙班, 5-氯-N-(((5S)-2-氧代-3-(4-(3-氧代嗎啉-4-基)苯基)-1,3-惡唑啉-5-基)甲基)噻吩-2-甲酰胺;利伐沙班-D4;366789-02-8;利伐沙班標(biāo)準(zhǔn)品；

英文名：Rivaroxaban;5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl];Xarelto;(S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide;Rivaroxaban (BAY59-7939);BAY 59-7939 (Rivaroxaban);Rivarobaxan

類別：新藥及仿制藥-;對照品-雜質(zhì)對照品;原料藥;科研試劑;醫(yī)藥類別;利伐沙班;醫(yī)藥中間體;其他科研原料藥;利伐沙班中間體;醫(yī)藥原料;中間體;小分子抑制劑;醫(yī)藥原料藥;代謝;小分子抑制劑，天然產(chǎn)物;抗血栓藥物;惡唑啉;噻吩;含硫化合物,酰鹵;-;Inhibitors;抗凝藥;醫(yī)藥化工原料;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;API;Inhibitor;Rivaroxaban;Pharmaceutical raw materials